logo-loader
Synairgen PLC

Synairgen reports strong interest in new fibrosis treatment ahead of Phase I trial

PXS-5382A, an inhibitor that aids breathing in patients by targeting the LOXL2 enzyme, is being developed with Australian firm Pharmaxis.

picture of lungs
Synairgen's new drug might potentially treat a number of indications

Synairgen PLC (LON:SNG) has reported significant industry interest in its new idiopathic pulmonary fibrosis treatment ahead of the start of clinical trials.

Richard Marsden, Synairgen’s chief executive, said: "Based on PXS-5382A's potential across a number of disease areas and the promising data seen to date, we have received significant interest from companies looking to license the programme for multiple indications.”

READ: Synairgen pleased with the progress made with the LOXL2 programme

The respiratory drug developer confirmed in a statement that it is to start a Phase I (safety) trial of the new treatment for sufferers of idiopathic pulmonary fibrosis in the fourth quarter of 2017 after completing pre-clinical studies.

PXS-5382A, an inhibitor that aids breathing in patients by targeting the LOXL2 enzyme, is being developed with Australian firm Pharmaxis.

Results from the Phase I trial are scheduled for the middle of 2018, after which the aim is to find a partner to license the drug due to size of the potential market and number of indications it could address.

WATCH: Synairgen's chief hails exciting IPF data from LOXL2 inhibitor programme

Though IPF is the initial target, LOXL2 is believed to be an important factor in other fibrotic diseases such as NASH, cardiac fibrosis and kidney fibrosis, all of which are areas of high unmet need currently.

“PXS-5382A is a very valuable candidate with potential applications in a number of fibrotic conditions with very substantial market opportunities,” said Marsden. 

"The effect of this novel inhibitor across different model types is very exciting, with the latest supporting data suggesting that PXS-5382A can significantly reduce lung fibrosis and therefore has the potential to improve lung function in severely ill patients.”

Quick facts: Synairgen PLC

Price: £0.09

Market: AIM
Market Cap: £10.12 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Synairgen PLC named herein, including the promotion by the Company of Synairgen PLC in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Synairgen PLC pleased with further positive data from lead COPD drug

Richard Marsden, chief executive of Synairgen plc (LON:SYN), tells Proactive's Andrew Scott data from the ongoing phase II study of their SNG001 drug suggests it's having the desired effect in boosting the antiviral defences of chronic obstructive pulmonary disease (COPD)...

on 28/6/18

2 min read